177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called 177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving 177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating cancer stem cells in patient's blood for the trea

Trial Details

NCT ID
NCT04529044
Phase
PHASE2
Sponsor
OHSU Knight Cancer Institute
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Biopsy
  • Biospecimen Collection
  • Computed Tomography
  • Gallium Ga 68-DOTATATE
  • Lutetium Lu 177 Dotatate
  • Positron Emission Tomography
Locations (sample)
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Life expectancy of \> 6 months, as determined by the investigator
  • Ability to understand and the willingness to sign a written informed consent document
  • Patients aged \>= 18-100 years old at time of informed consent
  • Histologically or cytologically confirmed metastatic breast carcinoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →